Peptidomimetic Nav1.6 Modulators for Neuropsychiatric Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications for psychiatric disorders lack specificity, leading to broad and indiscriminate effects on brain circuits, resulting in unwanted side effects due to the lack of selective targeting of Nav1.6 sodium channels, which are associated with various neurological and psychiatric disorders.
Innovation Solution
Development of novel peptidomimetic compounds that selectively target the FGF14:Nav1.6 complex, modulating Nav1.6 channels alone or in synergy with accessory proteins like FGF14 to regulate neuronal excitability and treat conditions such as mood disorders, depression, anxiety, addiction, and epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications are used to treat psychiatric disorders, then therapeutic effects are achieved, but side effects increase due to lack of specificity
Solution Approach 1:
The patent applies local quality by designing peptidomimetic compounds that selectively target the FGF14:Nav1.6 complex interface, creating a localized therapeutic effect at the specific molecular interaction site. This selectivity allows the medication to affect only the specific neuronal pathways involved in psychiatric disorders without broadly impacting other brain circuits, thereby reducing side effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of peptidomimetic compounds to alter their binding affinity and selectivity for the FGF14:Nav1.6 complex. By adjusting molecular parameters such as binding kinetics and interaction strength, the compounds achieve precise modulation of Nav1.6 channel function, enabling effective treatment with minimal off-target effects.
2Adaptability or versatility
If broad-spectrum medications are used, then multiple conditions can be treated, but specificity and precision of action are reduced
Solution Approach 1:
The patent applies universality by developing a selective FGF14:Nav1.6 complex-targeting approach that can treat multiple psychiatric disorders (depression, anxiety, addiction, epilepsy) through a single mechanism of action. This multi-functional strategy allows one targeted therapeutic approach to address diverse conditions sharing common neural circuitry involvement, maintaining treatment versatility while achieving high targeting accuracy through molecular selectivity.
3Object-affected harmful factors
If selective targeting of Nav1.6 channels is achieved, then side effects are reduced, but development complexity increases
Solution Approach 1:
The patent applies the intermediary principle by utilizing FGF14 as a molecular mediator or bridge in the drug-target interaction. The peptidomimetic compounds interact with the FGF14:Nav1.6 complex, leveraging the accessory protein FGF14 as an intermediary element that facilitates selective binding to Nav1.6 channels. This approach simplifies the development process by providing a clear molecular anchor point for selectivity while maintaining reduced side effects through precise targeting.
Data Source
AI summary
The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof.